Gilead Sciences (GILD) Misses Q4 EPS by 27c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Gilead Sciences (GILD) Misses Q4 EPS by 27c, Offers FY Guidance
February 5, 2019 9:00 AM EST
Raymond James analyst Steven Seedhouse lowered the price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $92.00) while maintaining a Strong Buy rating.
...
More
February 5, 2019 6:59 AM EST
Citi analyst Robyn Karnauskas lowered the price target on Gilead Sciences (NASDAQ: GILD) to $100.00 (from $106.00) while maintaining a Buy rating. 2019 guidance anticipates double-digit y/y HIV growth and HCV stabilization. The company guided for generic impact in HCV, Letairis and Ranexa of ~$2.2B with... More
February 5, 2019 6:46 AM EST
RBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $89.00 (from $86.00) while maintaining a Outperform rating following fourth quarter results.
Abrahams commented, "Parsing out the one-time effects that inflated HIV but depressed earnings this quarter,... More
February 4, 2019 4:03 PM EST
Gilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.63 per share, or $2.52 annualized. This is a 10.5% increase from the prior dividend of $0.57.
The dividend will be payable on March 28, 2019, to stockholders of record on March 15, 2019, with an ex-dividend date of March 14,... More
